5-(3-(3-(2-quinolinylmethyloxy)benzyloxy)styryl)tetrazole hydrochloride | 1097908-21-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-(3-(3-(2-quinolinylmethyloxy)benzyloxy)styryl)tetrazole hydrochloride
• 英文别名: 2-[[3-[[3-[(E)-2-(2H-tetrazol-5-yl)ethenyl]phenoxy]methyl]phenoxy]methyl]quinoline;hydrochloride
• CAS: 1097908-21-8
• 化学式: C₂₆H₂₁N₅O₂*ClH
• 分子量: 471.946
• InChiKey: RJMGSTIOSMEEAO-JHGYPSGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  85.8
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-(3-(2-quinolinylmethyloxy)benzyloxy)cinnamylnitrile 在 三氯化铝 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成 5-(3-(3-(2-quinolinylmethyloxy)benzyloxy)styryl)tetrazole hydrochloride
  参考文献：
  名称：

  Quinoline derivatives and their use as antagonists of leukotriene D.sub.4

  摘要：

  本发明涉及喹啉基二芳基化合物及其作为白三烯D.sub.4拮抗剂治疗过敏性疾病的用途。

  公开号：

  US05059610A1

文献信息

• Therapeutic uses of quinoline derivatives
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US06376512B1

  公开（公告）日：2002-04-23

  A method for mediating the activity of PPAR-&ggr; receptor comprising contacting said PPAR-&ggr; receptor with a compound of formula I defined herein. Also disclosed is the treatment of a patient suffering from a physiological disorder capable of being modulated by a compound of formula I having PPAR-&ggr; ligand binding activity, comprising administering to the patient a pharmaceutically acceptable amount of the compound, or a pharmaceutically acceptable salt thereof.

  一种调节PPAR-γ受体活性的方法，包括将所述PPAR-γ受体与本文定义的I式化合物接触。还公开了治疗患有可被具有PPAR-γ配体结合活性的I式化合物调节的生理紊乱的患者的方法，包括向患者施用药学上可接受的量的该化合物或其药学上可接受的盐。
• Quinoline derivatives and their use as antagonists of leukotriene D.sub.4
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US05059610A1

  公开（公告）日：1991-10-22

  This invention relates to quinolinyl-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.

  本发明涉及喹啉基二芳基化合物及其作为白三烯D.sub.4拮抗剂治疗过敏性疾病的用途。
• Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same
  申请人：RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC.

  公开号：EP0315399A2

  公开（公告）日：1989-05-10

  This invention relates to quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same. The quinoline derivatives of the invention are a particular class of quinolinyl-diaryl compounds and they are especially valuable as lipoxygenase inhibitors and/or leukotriene antagonists, typically antagonists of leukotriene D4, possessing anti-inflammatory and anti-allergic properties.

  本发明涉及喹啉衍生物、它们在治疗过敏性疾病中的用途以及含有喹啉衍生物的药物组合物。 本发明的喹啉衍生物是一类特殊的喹啉基二元化合物，它们作为脂氧合酶抑制剂和/或白三烯拮抗剂（通常是白三烯 D4 拮抗剂）特别有价值，具有抗炎和抗过敏特性。
• HUANG, FU-CHI;GALEMMO, ROBERT A. (JR);CAMPBELL, HENRY F.
  作者：HUANG, FU-CHI、GALEMMO, ROBERT A. (JR)、CAMPBELL, HENRY F.

  DOI：——

  日期：——
• THERAPEUTIC USES OF QUINOLINE DERIVATIVES
  申请人：Aventis Pharmaceuticals Products Inc.

  公开号：EP1030665A1

  公开（公告）日：2000-08-30